Clinical laboratories are reimbursed for providing services to Medicare beneficiaries using either the Physician Fee Schedule (PFS) or the Clinical Laboratory Fee Schedule (CLFS), depending on the nature of the service. In addition, clinical laboratories provide services to beneficiaries of other government programs such as Medicaid, TRICARE and the Federal Employee Health Benefit Plan (FEHBP),…
Clinical laboratories are reimbursed for providing services to Medicare beneficiaries using either the Physician Fee Schedule (PFS) or the Clinical Laboratory Fee Schedule (CLFS), depending on the nature of the service. In addition, clinical laboratories provide services to beneficiaries of other government programs such as Medicaid, TRICARE and the Federal Employee Health Benefit Plan (FEHBP), as well as commercial plans.
Lab reimbursement in many of these programs has been reduced in recent years, and in the case of the Medicare program, annual cuts are scheduled in current law not only as a result of sequestration, but also through annual cuts built into the Affordable Care Act.
While payments for lab services are being slashed, the costs associated with providing critical laboratory services - including labor, supplies, and transportation - continue to climb.
Although many labs have managed to navigate changes in markets and reimbursement and while still continually improving quality, continued arbitrary and severe payment reductions will result in reduced access to essential tests for critically ill patients, less innovation, more closures or consolidation of businesses, and more people out of jobs.
-
ACLA Comments on Medicare Coverage of Innovative Technology (MCIT)
-
ACLA Statement on President Biden’s Actions to Close Coverage Gaps for COVID-19 Testing
Washington, D.C. Following the Biden Administration’s new guidance on coverage requirements for COVID-19 testing, ACLA President Julie Khani released the following statement: “President Biden’s decisive ... Read More -
ACLA Comment Letter on Reconsideration Request for New Therapeutic Drug and Molecular Pathology CPT Codes
-
Protecting Our Nation Through Robust Access to COVID-19 Testing
Access to reliable and accurate COVID-19 testing remains critically important to all Americans. However, absent federal assurance that COVID-19 tests will be covered, patients continue ... Read More -
Maintaining and Expanding Access to COVID-19 Testing: The Critical Need for Sustainable Reimbursement
Since the start of the pandemic, ACLA laboratories have focused on developing and offering a range of new tests and techniques to directly support patients ... Read More -
ACLA Statement on Medicare Reimbursement Rate For Serologic Testing
WASHINGTON, D.C. – Following the release by the Centers for Medicare and Medicaid Services (CMS) of a reimbursement rate of $42.13 for the most commonly-performed ... Read More